08:00 , Nov 5, 2012 |  BC Week In Review  |  Company News

BioXpress Therapeutics, AET Group deal

BioXpress and the AET BioTech biosimilars business of generics company Alfred E. Tiefenbacher partnered to co-develop a biosimilar version of autoimmune drug adalimumab, a human mAb against tumor necrosis factor (TNF) alpha. AET BioTech...
00:35 , Oct 31, 2012 |  BC Extra  |  Company News

BioXpress, AET BioTech to co-develop adalimumab biosimilar

BioXpress Therapeutics S.A. (Plan-les-Ouates, Switzerland) and AET BioTech partnered to co-develop a biosimilar version of autoimmune drug adalimumab, a human mAb against tumor necrosis factor (TNF) alpha. AET BioTech will provide "committed long term" funding...